Roivant's experimental lung disease drug meets goals in mid-stage study

Roivant's experimental drug met the primary endpoints in a mid-stage trial for high blood pressure associated with a lung disease. The positive clinical readout drove Roivant shares about 20% higher in premarket trading, materially improving the program's development outlook.